Journal
JOURNAL OF RHEUMATOLOGY
Volume 36, Issue 11, Pages 2397-2402Publisher
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.090132
Keywords
BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; CHEMOKINE LIGAND 20; FIBROBLAST-LIKE SYNOVIAL CELLS; PROINFLAMMATORY CYTOKINES; RHEUMATOID ARTHRITIS
Categories
Ask authors/readers for more resources
Objective. Chemokine ligand 20 (CCL20) is a selective ligand for chemokine receptor 6 (CCR6). We investigated, both in vitro and in vivo, whether CCL20 is critically involved in the disease process of rheumatoid arthritis (RA). Methods. In vitro study investigated the effect of proinflammatory cytokines and biologic disease-modifying antirheumatic drugs (DMARD) oil the production of CCL20 by rheumatoid fibroblast-like synovial cells (FLS). The in vivo role of CCL20 was studied by screening for serum CCL20 concentration in patients with RA during the therapeutic course of biologic DMARD, i.e., infliximab, etanercept, and tocilizumab. Results. Spontaneous CCL20 production from rheumatoid FLS was minimal however, its production was significantly stimulated by interleukin 1 beta (IL-1 beta) tumor necrosis factor-alpha (TNF-alpha), or IL-17. 1L-I beta was the most potent for stimulating the production of CCL20. CCL20 production was synergistically augmented by a combination of IL-1 beta, TNF-alpha, and IL-17. In contrast, interferon-gamma suppressed IL-1 beta-induced CCL20 production. IL-6, ill combination with soluble IL-6 receptor (sIL-6R), did not modulate CCL20 production, whereas IL-1 beta-induced, TNF-alpha-induced, and IL-17-induced production were increased by IL-6. These production levels were clearly suppressed by biologic DMARD in vitro. Serum CCL20 was significantly higher in RA than in control subjects, and was clearly decreased by the treatment with infliximab, etanercept, and tocilizumab. Conclusion. Proinflammatory cytokines modulate the production of CCL20 from FLS. Our data suggest that therapeutic efficacy of biologic DMARD may result from the inhibition of CCL20 production ill rheumatoid synovium. (First Release Oct 1 2009; J Rheumatol 2009;36:2397-402; doi: 10.3899/jrheum.090132)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available